Literature DB >> 15649309

Isolation of an amikacin-resistant Escherichia coli strain after tobramycin treatment of previous recurrent episodes of respiratory tract infections caused by Pseudomonas aeruginosa.

J Ruiz1, S Bertran, G Sauca, A Julià, X Vila, E Gómez, M T Jiménez de Anta, J Vila.   

Abstract

Amikacin-resistant Escherichia coli strains are isolated rarely from clinical samples. In the present study, investigation of an amikacin-resistant clinical isolate of E. coli demonstrated the presence of two class 1 integrons carrying the aacA4 gene plus the aacA7 gene, and the dfrA17 gene plus the aadA5 gene, respectively. Resistance to amikacin in this E. coli isolate was related to the presence of both aacA4 and aacA7.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15649309     DOI： 10.1111/j.1469-0691.2004.01039.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN： 1198-743X            Impact factor:   8.067


  3 in total

1.  The Link between Occurrence of Class I Integron and Acquired Aminoglycoside Resistance in Clinical MRSA Isolates.

Authors:  Ahmed M El-Baz; Galal Yahya; Basem Mansour; Mohamed M A El-Sokkary; Reem Alshaman; Abdullah Alattar; Amira M El-Ganiny
Journal:  Antibiotics (Basel)       Date:  2021-04-23

2.  Antibacterial Efficacy of Liposomal Formulations Containing Tobramycin and N-Acetylcysteine against Tobramycin-Resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii.

Authors:  Reem E Alarfaj; Manal M Alkhulaifi; Ahmed J Al-Fahad; Shokran Aljihani; Alaa Eldeen B Yassin; Majed F Alghoribi; Majed A Halwani
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321

3.  Pan-genome and resistome analysis of extended-spectrum ß-lactamase-producing Escherichia coli: A multi-setting epidemiological surveillance study from Malaysia.

Authors:  Jacky Dwiyanto; Jia Wei Hor; Daniel Reidpath; Tin Tin Su; Shaun Wen Huey Lee; Qasim Ayub; Faizah Binti Mustapha; Sui Mae Lee; Su Chern Foo; Chun Wie Chong; Sadequr Rahman
Journal:  PLoS One       Date:  2022-03-10       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.